To improve the DMPK characteristics, many studies have explored the coupling of PROTAC payloads with monoclonal antibodies to create a new molecule known as “Antibody-Drug Conjugates (DAC).” This allows for more effective delivery of PROTAC degraders in vivo. â–˛ Structure of DAC (Image Source: Reference 1) Compared to PROTAC molecules, DAC has several potential advantages: … Read more
The Emergence and Advantages of DAC Cancer therapeutics need to achieve a balance between efficacy and safety, even targeted chemotherapy does not always only kill abnormal cancer cells, non-specific toxicity can lead to a low therapeutic index and side effects. The technology of proteolysis-targeting chimeras (PROTACs), which achieves therapeutic effects by promoting the degradation of … Read more
1. Mechanism of ADC Action Antibody-drug conjugates (ADC) (Click to enter the database to search for global ADC drug information) enter the body, the antibody part binds to the targeted antigen on the surface of tumor cells, tumor cells will endocytose the ADC molecule. Among them, some can bind to Fc receptors in the endosome, … Read more
ADCs (Antibody-Drug Conjugates) and RDCs (Radionuclide Conjugates) are innovative drugs that have gained significant attention in recent years, demonstrating enormous potential in the field of oncology. They are referred to as the “magic bullets” of tumor-targeted therapy because they enable precise treatment while avoiding damage to normal cells. ADC drugs link antibodies with known effective … Read more
The development of ADC drugs has not been smooth sailing, with nearly 100 years of history since the concept of the “magic bullet” was proposed, but ultimately, the clouds have parted to reveal the moon. DS8201 has redefined ADC, but it is not the end of ADC drugs, rather a new beginning. A comprehensive understanding … Read more
ADC Field Blooms, new technologies evolve like a rolling tide, propelling biomedicine into high-speed mode. This is the best of times. As early as the early 20th century, Paul Ehrlich first proposed the concept of “magic bullets”; however, the first ADC drug, Mylotarg® (gemtuzumab ozogamicin), was not approved until nearly a century later. Every cloud … Read more
Introduction Antibody-drug conjugates (ADC) combine the high specificity of monoclonal antibodies with the high potency of small molecule cytotoxic drugs to enhance the targeting of cancer therapies and reduce side effects. Compared to traditional antibodies or antibody fragments, ADCs can release highly active cytotoxins within tumor tissues, theoretically leading to higher efficacy. ADCs have undergone … Read more
ADC (Antibody-drug conjugate) is a new type of drug for cancer treatment. It is a complex formed by combining anti-tumor drugs with antibodies, allowing for precise delivery of the drug into tumor cells, thereby achieving targeted treatment of tumor cells. However, with the widespread application of ADCs, research has found that the issue of ADC … Read more
Antibody-drug conjugates (ADC) are formed by the coupling of specific targeting monoclonal antibodies and highly active cytotoxic drugs through linkers. With their unique pharmaceutical properties, ADC drugs exhibit strong anti-tumor activity in the field of cancer therapy, while also offering higher safety compared to traditional chemotherapy. In recent years, the development of ADC drugs in … Read more
*For reference only by medical professionals The latest review reports that ADC drug resistance is related to antigen expression, ADC processing, and payload efficacy. Antibody-drug conjugates (ADC) are formed by the conjugation of specific targeting monoclonal antibodies and highly active cytotoxic drugs via linkers. With their unique pharmacological properties, ADC drugs exhibit powerful anti-tumor activity … Read more